clinical practice guidelines
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

https://doi.org/10.1093/annonc/mdq174Get rights and content
Under an Elsevier user license
open archive

Cited by (0)

Approved by the ESMO Guidelines Working Group: February 2002, last update March 2010. This publication supercedes the previously published version—Ann Oncol 2009; 20 (Suppl 4): iv76-iv78.

Conflict of interest: Prof. Horwich has reported that his institution is the inventor of the drug Abiraterone which is being investigated in prostate cancer and may lead to royalties payment to the institute; Dr Parker has reported that he is a consultant for Algeta and that he has received honoraria from Takeda, Bayer and Johnson & Johnson; Prof. Bangma and Dr Kataja have reported no conflicts of interest.